SPBC21C3.17c Antibody

What is the SPBC21C3.17c protein and how are antibodies against it generated?

SPBC21C3.17c belongs to the IL-17 family of cytokines, which shares structural similarities with other IL-17 family members. Antibodies against this protein are typically generated using E. coli-derived recombinant protein as the immunogen, similar to how human IL-17C antibodies are produced . The protein sequence used for immunization typically includes amino acids corresponding to the mature protein, excluding the signal peptide. Monoclonal antibodies provide more consistent results than polyclonal preparations, with clone selection being critical for specificity across different applications .

What are the recommended storage conditions for SPBC21C3.17c antibodies to maintain activity?

SPBC21C3.17c antibodies should be stored following strict protocols to maintain functionality. Based on similar research antibodies, the following conditions are recommended:

• Long-term storage: -20°C to -70°C for up to 12 months from the date of receipt

• Medium-term storage: 2-8°C under sterile conditions for up to 1 month after reconstitution

• Extended storage: -20°C to -70°C under sterile conditions for up to 6 months after reconstitution

It is critical to use a manual defrost freezer and avoid repeated freeze-thaw cycles, as each cycle can reduce antibody activity by approximately 10-15% .

What cross-reactivity concerns should researchers consider when using SPBC21C3.17c antibodies?

When working with SPBC21C3.17c antibodies, researchers should be aware of potential cross-reactivity with homologous proteins from the same family. Similar to IL-17C, which shares 15-30% amino acid sequence identity with other IL-17 family members, SPBC21C3.17c may share structural similarities with related proteins . Researchers should validate antibody specificity using appropriate controls, including isotype controls (such as MAB003 used for IL-17C studies) and blocking peptides specific to the immunogen sequence . Epitope mapping is recommended to identify specific binding regions and predict potential cross-reactivity with homologous proteins.

How should researchers optimize immunohistochemistry protocols for SPBC21C3.17c detection in tissue samples?

For optimal immunohistochemical detection of SPBC21C3.17c in tissue samples, researchers should:

• Perform heat-induced epitope retrieval using appropriate retrieval reagents (similar to VisUCyte Antigen Retrieval Reagent-Basic for IL-17C detection)

• Optimize antibody concentration (starting at 10 μg/ml as used for IL-17C detection) and incubation time (typically 1 hour at room temperature)

• Select appropriate secondary detection systems (such as HRP Polymer Antibody systems)

• Include proper controls for background staining

• Use DAB (3,3'-diaminobenzidine) for visualization and hematoxylin as a counterstain

Researchers should expect specific staining localized to relevant cellular compartments, similar to how IL-17C staining is localized to the cytoplasm of lymphocytes in Crohn's disease samples .

What are the best approaches for quantifying SPBC21C3.17c expression in flow cytometry applications?

For flow cytometric analysis of SPBC21C3.17c, researchers should:

• Optimize cell fixation with paraformaldehyde (typically 4%)

• Determine appropriate permeabilization conditions (saponin is recommended for intracellular cytokine staining)

• Use titrated concentrations of primary antibody alongside isotype controls

• Select appropriate fluorophore-conjugated secondary antibodies (such as Allophycocyanin-conjugated Anti-Mouse IgG)

• Include single-color controls for compensation

• Analyze data using histogram overlays to compare specific staining against isotype controls

For multiparameter analysis, consider the emission spectra of all fluorophores to minimize spillover and optimize compensation settings.

How can researchers effectively validate SPBC21C3.17c antibody specificity for their experimental system?

Comprehensive validation of SPBC21C3.17c antibody specificity should include:

• Western blot analysis to confirm expected molecular weight

• Positive and negative cell/tissue controls with known expression patterns

• Competitive inhibition assays using purified recombinant protein

• siRNA knockdown or CRISPR knockout validation in relevant cell lines

• Multiple antibody approach using antibodies targeting different epitopes

• Cross-species reactivity assessment if working with conserved proteins

For ultimate validation, researchers should consider parallel detection methods such as mass spectrometry or RNA expression analysis to correlate protein and transcript levels.

What factors influence SPBC21C3.17c expression in mucosal immunity models, and how should researchers control for these variables?

Based on research with related proteins such as IL-17C, SPBC21C3.17c expression in mucosal immunity models may be influenced by:

• Pathogenic stimuli including bacterial components (e.g., flagellin) and viral mimetics (e.g., poly I:C through TLR3 activation)

• Pro-inflammatory cytokines (e.g., TNF-α, IL-1β)

• Inhibitory cytokines (e.g., IL-13) which may suppress expression through JAK1/2 and STAT6 signaling pathways

• Cell culture conditions (submerged vs. air-liquid interface for epithelial cells)

To control for these variables, researchers should:

• Standardize stimulation protocols with defined concentrations and timing

• Include cytokine-specific blocking antibodies to isolate individual effects

• Monitor activation of relevant signaling pathways (NFκB, JAK/STAT)

• Use multiple cell types and culture conditions to comprehensively characterize expression patterns

How can researchers address conflicting results between different detection methods for SPBC21C3.17c?

When facing discrepancies between different detection methods for SPBC21C3.17c, researchers should:

• Evaluate epitope accessibility in different sample preparation methods

• Consider protein conformation differences between native and denatured states

• Assess sensitivity thresholds for each detection method

• Examine potential post-translational modifications affecting antibody recognition

• Investigate splice variants or proteolytic processing that might affect antibody binding

For resolution, researchers should:

• Perform parallel analysis with multiple antibodies targeting different epitopes

• Use orthogonal detection methods (e.g., mass spectrometry)

• Implement quantitative standards for each technique

• Consider genetic validation approaches (siRNA knockdown, CRISPR knockout)

What considerations are important when designing sandwich immunoassays for SPBC21C3.17c detection?

For developing effective sandwich immunoassays for SPBC21C3.17c, researchers should:

• Select capture and detection antibody pairs recognizing non-overlapping epitopes

• Optimize antibody concentrations through checkerboard titration

• Determine appropriate sample dilution factors to remain within the linear range

• Establish robust standard curves using recombinant protein

• Validate assay parameters including:

  • Lower limit of detection (LLOD)

  • Lower limit of quantification (LLOQ)

  • Dynamic range

  • Recovery rates in complex matrices

  • Intra-assay and inter-assay coefficient of variation (CV)

Additionally, researchers should validate the immunoassay in their specific sample types, as matrix effects can significantly impact assay performance.

How does SPBC21C3.17c functionally compare to other members of its protein family in experimental systems?

When comparing SPBC21C3.17c to related proteins such as IL-17C, researchers should consider:

• Receptor binding specificity and affinity measurements

• Downstream signaling pathway activation profiles

• Induction of target genes including antimicrobial peptides (e.g., human beta-defensin 2, lipocalin 2, granzyme B)

• Cell type-specific responses in different tissues

• Temporal expression patterns during immune responses

The table below summarizes key functional differences observed between IL-17C and other IL-17 family members in experimental systems, which may guide functional studies of SPBC21C3.17c:

What are the most sensitive methodologies for detecting low-abundance SPBC21C3.17c in complex samples?

For detection of low-abundance SPBC21C3.17c in complex biological samples, researchers should consider:

• Enhanced chemiluminescence (ECL) western blotting with signal amplification

• Enzyme-linked immunosorbent assay (ELISA) with amplification steps

• Immunoprecipitation followed by mass spectrometry

• Proximity ligation assay (PLA) for in situ detection with amplification

• Digital ELISA platforms (e.g., Simoa) for single-molecule detection

• Multiplex bead-based immunoassays for increased sensitivity and throughput

Each method offers specific advantages, and selection should be based on sample type, available equipment, and research questions. Researchers should validate recovery rates using spike-in controls with known quantities of recombinant protein.

How should researchers interpret SPBC21C3.17c expression patterns in diseased versus healthy tissues?

When analyzing SPBC21C3.17c expression in disease contexts, researchers should:

• Establish baseline expression in healthy tissues through multiple donors and sample types

• Quantify fold-changes relative to appropriate controls

• Correlate expression with disease markers and clinical parameters

• Perform cell-type specific analysis using co-staining approaches

• Consider temporal dynamics during disease progression

Based on studies of related proteins like IL-17C, researchers should analyze expression in the context of:

• Autoinflammatory and autoimmune conditions (e.g., inflammatory bowel disease, psoriasis)

• Infectious disease responses

• Tissue-specific regulation at mucosal and barrier surfaces

Distinguishing between protective and pathogenic roles requires careful correlation with disease phenotypes and functional validation in relevant model systems.

What approaches are recommended for establishing the role of SPBC21C3.17c in complex immune networks?

To elucidate SPBC21C3.17c's role in immune networks, researchers should:

• Perform comprehensive cytokine profiling before and after SPBC21C3.17c modulation

• Use systems biology approaches including RNA-seq and proteomics

• Evaluate effects on signaling pathway activation using phospho-flow cytometry

• Assess functional outcomes in relevant cell types (antimicrobial peptide production, cytokine secretion)

• Investigate interplay with other immune mediators, similar to IL-17C's interactions with IL-1β and IL-13

Network analysis should examine both upstream regulators and downstream effectors to position SPBC21C3.17c within existing immune paradigms.

How can researchers effectively use SPBC21C3.17c antibodies to assess therapeutic potential in disease models?

For evaluating SPBC21C3.17c as a therapeutic target, researchers should:

• Use neutralizing antibodies in relevant disease models to assess functional outcomes

• Develop conditional knockout systems to study tissue-specific effects

• Compare phenotypes between genetic deletion and antibody neutralization

• Establish clear biomarkers of target engagement and efficacy

• Consider combination approaches with established therapeutics

Based on the complex role of IL-17C in both protective immunity and inflammatory pathology, researchers should carefully evaluate both beneficial and potentially harmful effects of SPBC21C3.17c modulation in specific disease contexts.